Clinical commentary on ‘Late-onset neutropenia and neurological relapse during long-term rituximab therapy in MOG antibody spectrum disorder’

Abstract

Keywords

Multiple sclerosis immunology neuromyelitis optica (NMO)

Get full access to this article

View all access options for this article.

References

Damato

Evoli

Iorio

Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: A systematic review and meta-analysis. JAMA Neurol 2016; 73: 1342–1348.

Hacohen

Wong

Lechner

et al . Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol 2018; 75: 478–487.

Granqvist

Boremalm

Poorghobad

et al . Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurol 2018; 75: 320–327.

Biotti

Lerebours F

Bonneville F

et al . Late-onset neutropenia and neurological relapse, during long-term rituximab therapy in myelinoligodendrocyte glycoproteinantibody spectrum disorder. Mult Scler 2018; 24: 1645–1647.

Salmon

Cacoub

Combe

et al . Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: Data from the AutoImmunity and Rituximab registry. RMD Open 2015; 1: e000034.